方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| Caco-2 细胞渗透性测定× | 体外-体内相关性× | |
|---|---|---|
| 领域 | 药理学 | 药理学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1989 | 1995 |
| 提出者≠ | Ingrid Hidalgo | Gordon Amidon |
| 类型≠ | absorption screening | bioavailability prediction |
| 开创性文献≠ | Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749. DOI ↗ | Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3), 413-420. DOI ↗ |
| 别名≠ | Caco-2 assay, intestinal permeability, ADME screening | IVIVC |
| 相关 | 3 | 3 |
| 摘要≠ | The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport. | IVIVC is a mathematical relationship between in vitro and in vivo properties of a drug, developed to predict oral bioavailability from dissolution data. Introduced by Amidon and colleagues in the 1995 Biopharmaceutics Classification System, it bridges laboratory measurements and clinical outcomes to streamline drug development. |
| ScholarGate数据集 ↗ |
|
|